Merck's Keytruda Gains EU and US Approvals for New Formulations and Indications
TL;DR
Merck received positive EU CHMP opinions for its cancer drug KEYTRUDA, including approval for subcutaneous administration and a new indication for earlier-stage head and neck cancer, potentially expanding treatment options in Europe.
- Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer Merck.com
- FDA OKs New Keytruda Shot for Cancer The New York Times
- US FDA approves Merck's new injectable version of Keytruda Reuters
- Pembrolizumab Earns 2 Positive CHMP Opinions in HNSCC, Other EU Indications OncLive
- Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season Business Wire
Want the full story? Read the original reporting
Read on Merck.com